Skip to content

Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers

Euphrosyne Gouzoulis‐mayfrank, Karsten Heekeren, Anna Neukirch, Martina Stoll, Carsten Stock, Maja Obradovic, K.-A. Kovar

Pharmacopsychiatry November 1, 2005 DOI: 10.1055/s-2005-916185 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Double-blind crossover study Peer reviewed
Sample size 9
Population Healthy volunteers
Interventions DMT (S)-ketamine
Topics 5-MeO-DMT DMT Esketamine Ketamine
Citations 198
Key points DMT and (S)-ketamine produce distinct symptom profiles: DMT models positive symptoms of schizophrenia, while (S)-ketamine models negative symptoms, attention deficits, and catatonia-like features.

Abstract

Introduction: Pharmacological challenges with hallucinogens are used as models for psychosis in experimental research. The state induced by glutamate antagonists such as phencyclidine (PCP) is often considered as a more appropriate model of psychosis than the state induced by serotonergic hallucinogens such as lysergic acid diethylamide (LSD), psilocybin and N,N-dimethyltryptamine (DMT). However, so far, the psychological profiles of the two types of hallucinogenic drugs have never been studied directly in an experimental within-subject design.

Methods: Fifteen healthy volunteers were included in a double-blind, cross-over study with two doses of the serotonin 5-HT2A agonist DMT and the glutamate N-methyl-D-aspartate (NMDA) antagonist (S)-ketamine.

Results: Data are reported for nine subjects who completed both experimental days with both doses of the two drugs. The intensity of global psychological effects was similar for DMT and (S)-ketamine. However, phenomena resembling positive symptoms of schizophrenia, particularly positive formal thought disorder and inappropriate affect, were stronger after DMT. Phenomena resembling negative symptoms of schizophrenia, attention deficits, body perception disturbances and catatonia-like motor phenomena were stronger after (S)-ketamine.

Discussion: The present study suggests that the NMDA antagonist model of psychosis is not overall superior to the serotonin 5-HT2A agonist model. Rather, the two classes of drugs tend to model different aspects or types of schizophrenia. The NMDA antagonist state may be an appropriate model for psychoses with prominent negative and possibly also catatonic features, while the 5-HT2A agonist state may be a better model for psychoses of the paranoid type.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • DMT and (S)-ketamine produced similar global psychological intensity but distinct profiles, with DMT more strongly modeling positive symptoms of schizophrenia and ketamine modeling negative symptoms and catatonia-like features.

    Synthesized

Comparable studies

Other randomized controlled trials on 5-MeO-DMT, most cited first.

Study Year Design Participants
Dose-Response Study of N,N-Dimethyltryptamine in Humans Experienced hallucinogen users 1994 Double-blind, saline placebo-controlled, randomized study n = 12
Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans Experienced hallucinogen users 1996 Randomized controlled trial n = 13
Pharmacokinetics of N,N-dimethyltryptamine in Humans. Healthy adults 2023 Phase I component of a phase I/IIa randomised, double-blind, placebo-controlled, parallel-group, dose-escalation trial n = 24
Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis Healthy volunteers 2007 Double-blind crossover study n = 15
Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. Healthy psychedelic-naïve participants 2024 Double-blind, placebo-controlled single ascending dose study n = 44

Citations in the library

Explore topics